Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

GOP Senator Says Alabama's Medical Marijuana Rollout Is 'Corrupt Or Incompetent' And That Cannabis Is Not Medicine

Published 02/02/2024, 14:11
Updated 02/02/2024, 15:40
© Reuters.  GOP Senator Says Alabama's Medical Marijuana Rollout Is 'Corrupt Or Incompetent' And That Cannabis Is Not Medicine

Benzinga - by Nina Zdinjak, Benzinga Staff Writer.

Alabama legalized medical marijuana in 2021. Fast-forward three years later, the industry suffered a series of setbacks including several lawsuits and challenges, due to the limited number of cannabis licenses and disputes over rightful recipients.

One of the fiercest cannabis opponents in Alabama's legislature, State Senator Larry Stutts (R) recently commented on the industry, continuing to express his criticism.

“This is just a setup for corruption,” he said during an interview with Mobile radio FM Talk 106.5’s “The Jeff Poor Show.”

“They’re either … corrupt or incompetent in how this is being rolled out. I mean, what’s it been, three years? I’d like to know how many dollars that have been spent already just trying to get it off the ground. I’m still opposed to it."

Stutts added he doesn't believe that legal medical marijuana is good public policy or that cannabis is indeed good medicine.

"I think drugs in general are a tremendous problem in our society. To call it ‘medical marijuana’ — it is going to make it more available in society. It is going to legitimize it to young people. ‘This is a medicine.’ It’s not. It’s marijuana. I’m still opposed to it for all those reasons.”

Stutts was the main sponsor of a bill approved by the Alabama Senate in 2022 that requires that all women between the ages of 13 and 50 to prove that they are not pregnant and not breastfeeding to buy medical cannabis.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Republican senator's comments come after the Department of Health and Human Services (HHS) recommended the DEA to reclassify cannabis to Schedule III under the federal Controlled Substances Act (CSA). Rescheduling marijuana to Schedule III would acknowledge some of its medical values and make it the same type of substance as Tylenol, ketamine, anabolic steroids and testosterone.

Currently, 40 states plus the District of Columbia have legalized medical marijuana in some form.

Gambling Comparison

“The rollout has just been a catastrophe, and if you objectively look at how it was going to be rolled out three years ago, you could see that coming — and that’s the same situation with gaming,” Stutt said. “Who is going to run it? Where are the facilities going to be located? How is it going to be managed? Who is going to decide who gets what? Those two issues are a mirror image of each other. You think a marijuana dispensary license is a big deal? Try getting a casino license. And see how big of a deal that is.”

Related Links:

Third Time Was Not The Charm: Alabama Judge Blocks Medical Marijuana Permits

Setback Strikes Alabama’s Medical Cannabis Industry, Licenses On Hold Yet Again

Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Photo: Courtesy of FabrikaSimf via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.